We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
(+9.5%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$58.4M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$54.6M |
| 3 |
Johnson & Johnson
JNJ
|
+$45.1M |
| 4 |
Alkermes
ALKS
|
+$27.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$72.5M |
| 2 |
Gilead Sciences
GILD
|
+$21.9M |
| 3 |
Perrigo
PRGO
|
+$21.6M |
| 4 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$19.4M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$9.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.12% |
| 2 | Real Estate | 3.08% |
| 3 | Financials | 1.53% |
| 4 | Technology | 0.04% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$163B
| $243M | 8.81% |
2,079,731
-200,000
| -9% | -$21.9M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $223M | 8.08% |
1,929,234
-65,600
| -3% | -$7.5M |
|
3
Biogen
BIIB
$30.7B
| $143M | 5.16% |
353,233
+13,750
| +4% | +$5.52M |
|
|
4
Viatris
VTRS
$20.7B
| $125M | 4.51% |
1,837,005
+826,900
| +82% | +$58.4M |
|
|
5
Vertex Pharmaceuticals
VRTX
$122B
| $111M | 4.01% |
897,903
+433,659
| +93% | +$54.6M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $106M | 3.82% |
584,305
+82,000
| +16% | +$14.2M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $104M | 3.77% |
343,686
-18,000
| -5% | -$5.37M |
|
8
Regeneron Pharmaceuticals
REGN
$77.4B
| $95.5M | 3.45% |
187,166
| – | – |
|
9
Incyte
INCY
$24.9B
| $91.8M | 3.32% |
880,461
-56,000
| -6% | -$5.8M |
|
|
10
Johnson & Johnson
JNJ
$617B
| $86.2M | 3.12% |
884,612
+450,000
| +104% | +$45.1M |
|
|
11
Teva Pharmaceuticals
TEVA
$41.2B
| $82M | 2.97% |
1,387,594
+390,000
| +39% | +$24.1M |
|
12
Amgen
AMGN
$209B
| $76.3M | 2.76% |
497,280
+145,501
| +41% | +$23.3M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.7B
| $73.2M | 2.65% |
534,977
| – | – |
|
|
14
Alkermes
ALKS
$8.39B
| $66.6M | 2.41% |
1,035,470
+447,000
| +76% | +$27.4M |
|
15
Pfizer
PFE
$142B
| $54.9M | 1.99% |
1,726,706
| – | – |
|
16
Illumina
ILMN
$31B
| $50.1M | 1.81% |
236,071
+99,099
| +72% | +$19.4M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $42.3M | 1.53% |
331,931
| – | – |
|
|
AKRX
18
DELISTED
Akorn Inc
AKRX
| $37.1M | 1.34% |
849,482
| – | – |
|
19
Bristol-Myers Squibb
BMY
$132B
| $35.6M | 1.29% |
535,240
| – | – |
|
|
CTRX
20
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $26.5M | 0.96% |
433,600
| – | – |
|
|
ENDP
21
DELISTED
Endo International plc
ENDP
| $26M | 0.94% |
325,873
+74,100
| +29% | +$6.4M |
|
22
Molina Healthcare
MOH
$10.2B
| $24.5M | 0.88% |
347,901
| – | – |
|
|
MDRX
23
DELISTED
Veradigm Inc. Common Stock
MDRX
| $24.3M | 0.88% |
1,778,200
| – | – |
|
|
RCPT
24
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $23.7M | 0.86% |
124,800
| – | – |
|
|
ACOR
25
DELISTED
Acorda Therapeutics
ACOR
| $22.7M | 0.82% |
5,674
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.
- Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
- Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
- Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
- Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
- Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
- Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
- Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.
Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.